<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00429065</url>
  </required_header>
  <id_info>
    <org_study_id>Hemato INCAN 01/2007</org_study_id>
    <nct_id>NCT00429065</nct_id>
  </id_info>
  <brief_title>Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients &lt; 61 Years Old.</brief_title>
  <official_title>Selection of Young Patients (&lt; 61 Years), With Good Prognosis Diffuse Large B Cell Lymphoma, According to the Immunophenotype (BCL-6 Negative) to be Treated With Chemoimmunotherapy, With R-CHOP. A Pilot Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Cancerologia de Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Nacional de Cancerologia de Mexico</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a specific subtype of lymphoma responds
      optimally to treatment with rituximab and chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment with rituximab and chemotherapy (R-CHOP)is the accepted treatment for young
      patients with diffuse large B cell Non-Hodgkin's Lymphoma. However not every patient benefits
      with this expensive therapy. Recent data suggest that patients with BCL-6 negative lymphoma
      are more sensitive to Rituximab therapy. It is also known that patients with
      high-intermediate and high IPI risk does not benefit form standard three weekly CHOP
      chemotherapy.

      In this study we intend to define a subgroup of patients in whom this therapy will be of
      maximum benefit.

      We will prospectively treat a group of patients with the following characteristics:

      &lt; 60 years old low and low intermediate IPI risk BCL-6 negative B-cell NHL Treatment regimen:
      R-CHOP (standard dosis) for 8 cycles
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2007</start_date>
  <completion_date>January 2007</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Screening</primary_purpose>
    <observational_model>Defined Population</observational_model>
    <time_perspective>Longitudinal, Prospective</time_perspective>
  </study_design_info>
  <enrollment>30</enrollment>
  <condition>Non-Hodgkin Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Large B cell Non-Hodgkin Lymphoma CD20+

          -  BCL-6 negative

          -  Age &lt; 61 years old

          -  ECOG 2 or less

          -  IPI low, low intermediate

          -  Stage II, III or IV

          -  Signed Informed Consent

        Exclusion Criteria:

          -  Stage I

          -  Previous treatment

          -  Lymphomatous central nervous system involvement

          -  Heart disease

          -  Kidney failure (serum creatinine &gt; 2 mg/dl)

          -  HIV +

          -  Viral Hepatitis

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro Sobrevilla-Calvo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional de Cancerologia Mexico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Silvia Rivas-Vera, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional de Cancerologia Mexico</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Silvia Rivas-Vera, MD</last_name>
    <phone>56 28 04 46</phone>
    <email>srivasv02@yahoo.com.mx</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pedro Sobrevilla-Calvo, MD</last_name>
    <phone>56 28 04 16</phone>
    <email>sobrevilla.pedro@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto Nacional de Cancerologia</name>
      <address>
        <city>Mexico City</city>
        <state>D.f.</state>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Winter JN, Weller EA, Horning SJ, Krajewska M, Variakojis D, Habermann TM, Fisher RI, Kurtin PJ, Macon WR, Chhanabhai M, Felgar RE, Hsi ED, Medeiros LJ, Weick JK, Reed JC, Gascoyne RD. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood. 2006 Jun 1;107(11):4207-13. Epub 2006 Jan 31. Erratum in: Blood. 2007 Mar 15;109(6):2292.</citation>
    <PMID>16449523</PMID>
  </reference>
  <reference>
    <citation>Lossos IS, Jones CD, Warnke R, Natkunam Y, Kaizer H, Zehnder JL, Tibshirani R, Levy R. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood. 2001 Aug 15;98(4):945-51.</citation>
    <PMID>11493437</PMID>
  </reference>
  <reference>
    <citation>Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D, Levy R. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med. 2004 Apr 29;350(18):1828-37.</citation>
    <PMID>15115829</PMID>
  </reference>
  <verification_date>January 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2007</study_first_submitted>
  <study_first_submitted_qc>January 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2007</study_first_posted>
  <last_update_submitted>January 30, 2007</last_update_submitted>
  <last_update_submitted_qc>January 30, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2007</last_update_posted>
  <keyword>Non-Hodgkin lymphoma</keyword>
  <keyword>rituximab</keyword>
  <keyword>immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

